[1] |
Vakharia PP, Silverberg JI. New and emerging therapies for paediatric atopic dermatitis[J]. Lancet Child Adolesc Health, 2019,3(5):343⁃353. doi: 10.1016/S2352⁃4642(19)30030⁃6.
|
[2] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000.
|
[3] |
中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 儿童特应性皮炎基层诊疗指南(2023年)[J]. 中华全科医师杂志, 2023,22(1):8⁃18. doi: 10.3760/cma.j.cn114798⁃20220915⁃00924.
|
[4] |
Yang EJ, Beck KM, Sekhon S, et al. The impact of pediatric atopic dermatitis on families: a review[J]. Pediatr Dermatol, 2019,36(1):66⁃71. doi: 10.1111/pde.13727.
|
[5] |
Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open⁃label study of single⁃dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy[J]. J Eur Acad Dermatol Venereol, 2021,35(2):464⁃475. doi: 10.1111/jdv.16928.
|
[6] |
Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial[J]. Lancet, 2022,400(10356):908⁃919. doi: 10.1016/S0140⁃6736(22)01539⁃2.
|
[7] |
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double⁃blinded, placebo⁃controlled phase 3 trial[J]. J Am Acad Dermatol, 2020,83(5):1282⁃1293. doi: 10.1016/j.jaad.2020.06. 054.
|
[8] |
Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long⁃term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open⁃label phase Ⅱa study and subsequent phaseⅢ open⁃label extension study[J]. Br J Dermatol, 2021,184(5):857⁃870. doi: 10.1111/bjd.19460.
|
[9] |
Zhou B, Peng C, Li L, et al. Efficacy and safety of dupilumab in chinese patients with atopic dermatitis: a real⁃world study[J]. Front Med (Lausanne), 2022,9:838030. doi: 10.3389/fmed.2022. 838030.
|
[10] |
Yang DY, Li L, Lu T, et al. Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real⁃world study[J]. Arch Dermatol Res, 2023,315(3):467⁃472. doi: 10.1007/s00403⁃022⁃02380⁃w.
|
[11] |
Song X, Liu B, Luan T, et al. Moderate⁃to⁃severe atopic dermatitis in different age groups treated with dupilumab in China[J]. Allergy, 2023,78(6):1696⁃1699. doi: 10.1111/all. 15660.
|
[12] |
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis[J]. N Engl J Med, 2014,371(2):130⁃139. doi: 10.1056/NEJMoa1314768.
|
[13] |
Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo⁃controlled, dose⁃ranging phase 2b trial[J]. Lancet, 2016, 387(10013):40⁃52. doi: 10.1016/S0140⁃6736(15)00388⁃8.
|
[14] |
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial[J]. JAMA Dermatol, 2020,156(1):44⁃56. doi: 10.1001/jamadermatol. 2019.3336.
|
[15] |
Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence⁃Based Clinical Practice Guidelines"[J]. J Am Acad Dermatol, 2004,50(3):391⁃404. doi: 10.1016/j.jaad.2003.08. 003.
|
[16] |
Lewis⁃Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use[J]. Br J Dermatol, 1995,132(6):942⁃949. doi: 10.1111/j.1365⁃2133.1995.tb16953.x.
|
[17] |
Lewis⁃Jones MS, Finlay AY, Dykes PJ. The infants' dermatitis quality of life index[J]. Br J Dermatol, 2001,144(1):104⁃110. doi: 10.1046/j.1365⁃2133.2001.03960.x.
|
[18] |
Tokura Y, Hayano S. Subtypes of atopic dermatitis: from phenotype to endotype[J]. Allergol Int, 2022,71(1):14⁃24. doi: 10.1016/j.alit.2021.07.003.
|
[19] |
Gu C, Wu Y, Luo Y, et al. Real⁃world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single⁃centre, prospective, open⁃label study[J]. J Eur Acad Dermatol Venereol, 2022,36(7):1064⁃1073. doi: 10.1111/jdv.18109.
|
[20] |
Napolitano M, Fabbrocini G, Neri I, et al. Dupilumab treatment in children aged 6⁃11 years with atopic dermatitis: a multicentre, real⁃life study[J]. Paediatr Drugs, 2022,24(6):671⁃678. doi: 10.1007/s40272⁃022⁃00531⁃0.
|
[21] |
Lasek A, Bellon N, Mallet S, et al. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6⁃11 years): data from a French multicentre retrospective cohort in daily practice[J]. J Eur Acad Dermatol Venereol, 2022,36(12):2423⁃2429. doi: 10.1111/jdv.18450.
|
[22] |
Hansel K, Patruno C, Antonelli E, et al. Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32⁃week real⁃world experience during the COVID⁃19 pandemic[J]. Clin Exp Dermatol, 2022,47(1):165⁃167. doi: 10.1111/ced.14862.
|
[23] |
Stingeni L, Hansel K, Antonelli E, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16⁃week real⁃life experience during the COVID⁃19 pandemic in Italy[J]. Dermatol Ther, 2021,34(5):e15035. doi: 10.1111/dth.15035.
|
[24] |
Ariëns L, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult⁃to⁃treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry[J]. Allergy, 2020,75(1):116⁃126. doi: 10.1111/all.14080.
|
[25] |
Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real⁃life French multicenter adult cohort[J]. J Am Acad Dermatol, 2019,81(1):143⁃151. doi: 10.1016/j.jaad.2019.02.053.
|
[26] |
刘擘, 宋晓婷, 李若瑜, 等. 度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022,55(4):295⁃298. doi: 10.35541/cjd.20210736.
|
[27] |
黄馨, 陈筱昀, 李亚萍, 等. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022,55(6):486⁃493. doi: 10.35541/cjd.20220021.
|
[28] |
Paller AS, Siegfried EC, Cork MJ, et al. Laboratory safety from a randomized 16⁃week phase Ⅲ study of dupilumab in children aged 6 months to 5 years with moderate⁃to⁃severe atopic dermatitis[J]. Paediatr Drugs, 2023,25(1):67⁃77. doi: 10.1007/s40272⁃022⁃00553⁃8.
|
[29] |
Olesen CM, Holm JG, Nørreslet LB, et al. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre[J]. J Eur Acad Dermatol Venereol, 2019,33(8):1562⁃1568. doi: 10.1111/jdv.15609.
|
[30] |
Ferrucci S, Casazza G, Angileri L, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single⁃center real⁃life experience[J]. J Clin Med, 2020,9(3):791. doi: 10.3390/jcm9030791.
|
[31] |
Nettis E, Ferrucci SM, Pellacani G, et al. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response[J]. J Eur Acad Dermatol Venereol, 2021,35(12):e896⁃e898. doi: 10.1111/jdv.17541.
|
[32] |
Fargnoli MC, Esposito M, Ferrucci S, et al. Real⁃life experience on effectiveness and safety of dupilumab in adult patients with moderate⁃to⁃severe atopic dermatitis[J]. J Dermatolog Treat, 2021,32(5):507⁃513. doi: 10.1080/09546634.2019.1682503.
|
[33] |
Wollenberg A, Marcoux D, Silverberg JI, et al. Dupilumab provides rapid and sustained improvement in SCORing atopic dermatitis outcomes in paediatric patients with atopic dermatitis[J]. Acta Derm Venereol, 2022,102:adv00726. doi: 10.2340/actadv.v102.854.
|
[34] |
Kamal MA, Kovalenko P, Kosloski MP, et al. The posology of dupilumab in pediatric patients with atopic dermatitis[J]. Clin Pharmacol Ther, 2021,110(5):1318⁃1328. doi: 10.1002/cpt. 2366.
|
[35] |
Paller AS, Wollenberg A, Siegfried E, et al. Laboratory safety of dupilumab in patients aged 6⁃11 years with severe atopic dermatitis: results from a phaseⅢ clinical trial[J]. Paediatr Drugs, 2021,23(5):515⁃527. doi: 10.1007/s40272⁃021⁃00459⁃x.
|
[36] |
Kamphuis E, Boesjes CM, Loman L, et al. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28⁃week clinical and biomarker results from the BioDay registry[J]. Pediatr Allergy Immunol, 2022,33(12):e13887. doi: 10.1111/pai.13887.
|
[37] |
Igelman S, Kurta AO, Sheikh U, et al. Off⁃label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review[J]. J Am Acad Dermatol, 2020,82(2):407⁃411. doi: 10.1016/j.jaad.2019.10.010.
|
[38] |
Parmar NV, Abdula MA, Al Falasi A, et al. Long⁃term real⁃world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: retrospective chart analysis from a single tertiary care center[J]. Dermatol Ther, 2022,35(5):e15415. doi: 10.1111/dth.15415.
|
[39] |
Chia SY, Wee L, Koh M. Dupilumab for children and adolescents with atopic dermatitis: an Asian perspective[J]. Dermatol Ther, 2021,34(3):e14933. doi: 10.1111/dth.14933.
|